The Genomics Services Market was valued at USD 8.5 Billion in 2024, and is projected to reach USD 25 Billion by 2034, rising at a CAGR of 11.50%.
The market is expanding due to the increasing prevalence of genetic disorders and the rising emphasis on personalized medicine. As the understanding of genetics deepens, the demand for genomic services is surging, particularly with the growing integration of precision medicine in treatment protocols. The global healthcare landscape is witnessing a shift toward more personalized approaches driven by advancements in genetic testing and gene sequencing technologies. These developments are paving the way for early diagnosis, targeted treatments, and improved patient outcomes. Governments and private organizations worldwide are investing heavily in genomic research, with an increasing focus on enhancing diagnostic accuracy and developing new therapies. As precision medicine gains traction, genomic services are becoming indispensable in research, clinical diagnostics, and therapeutic development, positioning the market for significant growth over the next decade.
The development of cutting-edge technologies, including next-generation sequencing (NGS), is a critical driver propelling the genomics services market forward. Biotechnology startups and established industry leaders are actively investing in research and development to refine these technologies and enhance their capabilities. The declining cost of sequencing has further accelerated the adoption of NGS, allowing researchers and clinicians to sequence DNA and RNA quickly and accurately. This technology can identify gene mutations or variations in a fraction of the time compared to traditional methods, making it a preferred choice in both research and clinical diagnostics. In 2023, the next-generation sequencing segment alone generated USD 2.7 billion, underscoring its pivotal role in advancing genomic research and personalized medicine. Additionally, other prominent service types include genotyping, microarrays, and Sanger sequencing, each contributing to the market’s growth by offering specialized solutions tailored to different research and clinical needs.
The genomics services market is divided between research and diagnostics, with the research segment accounting for 63.6% of the market share in 2024. The increasing investments from both government and private sectors in genomic research are driving the growth of this segment. Academic institutions and biotechnology companies are leveraging genomic services to study gene structure, function, and variation, facilitating the discovery of novel therapies and improving the understanding of genetic disorders. The rapid adoption of genomics in drug discovery and clinical research highlights the growing importance of genomic services in transforming modern healthcare.
The U.S. Genomics Services Market is also expected to witness robust growth, maintaining a CAGR of 11.5% through 2034. This growth is fueled by substantial government funding for genomic research, the availability of advanced research facilities, and increasing public awareness of precision medicine. The United States continues to lead the global genomics landscape, with its well-established infrastructure and strong collaborations between public and private entities contributing to the rapid advancement of genomic services. The growing emphasis on genomic research and the integration of precision medicine into clinical workflows reinforce the significance of genomics in healthcare and drug development, positioning the market for sustained growth in the coming years.
This product will be delivered within 2-4 business days.
The market is expanding due to the increasing prevalence of genetic disorders and the rising emphasis on personalized medicine. As the understanding of genetics deepens, the demand for genomic services is surging, particularly with the growing integration of precision medicine in treatment protocols. The global healthcare landscape is witnessing a shift toward more personalized approaches driven by advancements in genetic testing and gene sequencing technologies. These developments are paving the way for early diagnosis, targeted treatments, and improved patient outcomes. Governments and private organizations worldwide are investing heavily in genomic research, with an increasing focus on enhancing diagnostic accuracy and developing new therapies. As precision medicine gains traction, genomic services are becoming indispensable in research, clinical diagnostics, and therapeutic development, positioning the market for significant growth over the next decade.
The development of cutting-edge technologies, including next-generation sequencing (NGS), is a critical driver propelling the genomics services market forward. Biotechnology startups and established industry leaders are actively investing in research and development to refine these technologies and enhance their capabilities. The declining cost of sequencing has further accelerated the adoption of NGS, allowing researchers and clinicians to sequence DNA and RNA quickly and accurately. This technology can identify gene mutations or variations in a fraction of the time compared to traditional methods, making it a preferred choice in both research and clinical diagnostics. In 2023, the next-generation sequencing segment alone generated USD 2.7 billion, underscoring its pivotal role in advancing genomic research and personalized medicine. Additionally, other prominent service types include genotyping, microarrays, and Sanger sequencing, each contributing to the market’s growth by offering specialized solutions tailored to different research and clinical needs.
The genomics services market is divided between research and diagnostics, with the research segment accounting for 63.6% of the market share in 2024. The increasing investments from both government and private sectors in genomic research are driving the growth of this segment. Academic institutions and biotechnology companies are leveraging genomic services to study gene structure, function, and variation, facilitating the discovery of novel therapies and improving the understanding of genetic disorders. The rapid adoption of genomics in drug discovery and clinical research highlights the growing importance of genomic services in transforming modern healthcare.
The U.S. Genomics Services Market is also expected to witness robust growth, maintaining a CAGR of 11.5% through 2034. This growth is fueled by substantial government funding for genomic research, the availability of advanced research facilities, and increasing public awareness of precision medicine. The United States continues to lead the global genomics landscape, with its well-established infrastructure and strong collaborations between public and private entities contributing to the rapid advancement of genomic services. The growing emphasis on genomic research and the integration of precision medicine into clinical workflows reinforce the significance of genomics in healthcare and drug development, positioning the market for sustained growth in the coming years.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Service Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Genomics Services market report include:- 23andMe
- Agilent Technologies
- BGI Genomics
- Bio Rad Laboratories
- Color Genomics
- Danaher
- Eurofins Scientific
- F. Hoffmann-La Roche
- GE Healthcare
- GENEWIZ (Azenta)
- Illumina
- LGC
- Macrogen
- IQVIA
- QIAGEN
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | March 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 8.5 Billion |
| Forecasted Market Value ( USD | $ 25 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
